25 completed. 25 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 25 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema | Phase 4 | Completed | CSL Behring | 18 | 2025-04-28 | 2026-07-23 |
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) Ruconest - Hereditary Angioedema | Phase 4 | Completed | Bernstein Clinical Research Center | 5 | 2018-08-14 | 2024-11-15 |
| A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions C1-esterase inhibitor [recombinant] (C1-INH-R) - CVI - Common Variable Immunodeficiency | Phase 4 | Completed | IMMUNOe Research Centers | 20 | 2018-06-13 | 2021-02-15 |
| Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Omalizumab - Urticaria Chronic | Phase 4 | Completed | Johns Hopkins University | 18 | 2017-10-06 | 2021-06-14 |
| Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody benralizumab, placebo - Chronic Idiopathic Urticaria | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2017-09-12 | 2019-07-10 |
| Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Omalizumab, Placebos - Idiopathic Angioedema | Phase 4 | Completed | University of Wisconsin, Madison | 12 | 2017-03-30 | 2022-11-01 |
| Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Bilastine, Placebo - Allergic Rhinitis, Urticaria | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 19 | 2015-10-01 | 2017-04-18 |
| A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Omalizumab, Placebo - Urticaria | Phase 4 | Completed | Genentech, Inc. | 206 | 2015-05-18 | 2018-03-29 |
| Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment OMALIZUMAB - CHRONIC SPONTANEOUS URTICARIA | Phase 4 | Completed | Novartis Pharmaceuticals | 136 | 2015-04-22 | 2020-02-25 |
| Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Cetirizine, Desloratadine, Fexofenadine - Urticaria | Phase 4 | Completed | Grupo de Alergología Clínica y Experimental | 150 | 2013-08-01 | 2014-02-19 |
| Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Omalizumab - Chronic Urticaria | Phase 4 | Completed | University of Colorado, Denver | 10 | 2013-04-01 | 2020-12-04 |
| A Call Center During HAE Attacks (SOS HAE) phone to the call center - Hereditary Angioedema | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 200 | 2013-03-01 | 2016-12-13 |
| Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Icatibant - Hereditary Angioedema | Phase 4 | Completed | Massachusetts General Hospital | 19 | 2011-12-01 | 2016-10-18 |
| Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection - Hereditary Angioedema Types I and II | Phase 4 | Completed | CSL Behring | 46 | 2011-11-01 | 2017-02-06 |
| Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Levocetirizine, Levocetirizine plus Hydroxyzine - Chronic Urticaria | Phase 4 | Completed | Association Asthma, Bulgaria | 24 | 2011-03-01 | 2013-07-17 |
| Safety Study of Levocetirizine and Fexofenadine Levocetirizine Oral Tablet, Fexofenadine 60 Mg Oral Tablet, Placebo Oral Tablet - Pruritus, Chronic Urticaria | Phase 4 | Completed | Charite University, Berlin, Germany | 18 | 2011-02-01 | 2019-10-04 |
| A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE C1 inhibitor (human) [C1 INH] - Hereditary Angioedema | Phase 4 | Completed | Shire | 20 | 2009-08-31 | 2021-06-23 |
| Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Desloratadine - Urticaria | Phase 4 | Completed | Marcus Maurer | 30 | 2009-08-01 | 2011-10-03 |
| Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) 5-mg Desloratadine, 10-mg Desloratadine, 20-mg Desloratadine - Chronic Idiopathic Urticaria | Phase 4 | Completed | Organon and Co | 314 | 2007-09-01 | 2024-05-23 |
Showing 20 of 25. Sign in to see all of them.
Chronic Urticaria (9) · Angioedemas, Hereditary (7) · Rhinitis, Allergic (2) · Angioedema (1) · Cold Urticaria (1) · Common Variable Immunodeficiency (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hereditary Angioedema Types I and II (1) · Pruritus (1)
Hypersensitivity (25) · Hypersensitivity, Immediate (25) · Immune System Diseases (25) · Skin Diseases (25) · Skin Diseases, Vascular (25) · Skin and Connective Tissue Diseases (25) · Cardiovascular Diseases (9) · Chronic Disease (9) · Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Vascular Diseases (9) · Angioedema (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)
desloratadine (8) · Omalizumab (5) · Complement C1 Inhibitor Protein (3) · levocetirizine (3) · Cetirizine (2) · bilastine (2) · fexofenadine (2) · icatibant (2) · Hydroxyzine (1) · Injections (1) · SERPING1 protein, human (1) · Tablets (1) · Water (1) · benralizumab (1) · conestat alfa (1)
Organon and Co (4) · CSL Behring (2) · Charite University, Berlin, Germany (2) · Assistance Publique - Hôpitaux de Paris (1) · Association Asthma, Bulgaria (1) · Bernstein Clinical Research Center (1) · Genentech, Inc. (1) · Grupo de Alergología Clínica y Experimental (1) · IMMUNOe Research Centers (1) · Johns Hopkins University (1) · Jonathan A. Bernstein, MD (1) · Marcus Maurer (1) · Massachusetts General Hospital (1) · Menarini International Operations Luxembourg SA (1) · Nang Kuang Pharmaceutical Co., Ltd. (1)
United States (10) · Germany (5) · France (3) · Bulgaria (2) · Italy (2) · Romania (2) · Belgium (1) · Canada (1) · Colombia (1) · Hungary (1) · Malaysia (1) · Poland (1) · South Africa (1) · Spain (1) · Taiwan (1)
Marcus Maurer, MD (2) · Aleena Banerji, M.D. (1)
PMID 19133920, PMID 23147964, PMID 27140403, PMID 27326985, PMID 27788880, PMID 28709817, PMID 29503044, PMID 29671921, PMID 31034999, PMID 31109849, PMID 33713769, PMID 33737935, PMID 35914662
2008 (1), 2015 (1), R01AI116658 (1)